US Stock MarketDetailed Quotes

PEPG PepGen

Watchlist

8.890
+0.340+3.98%

Close Oct 1 16:00 ET

8.890
0.0000.00%

Post 16:22 ET

289.72MMarket Cap-2685P/E (TTM)

PepGen Stock Forum

Jaguar8

Jul 30 17:12

NEWS: (No Negative Findings) PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy

$PepGen (PEPG.US)$
Positive
▪️PGN-EDO51 achieved mean exon skipping levels of 2.15% after three months at 5 mg/kg dose
▪️Mean muscle-adjusted dystrophin level increased by 0.70% from baseline
▪️Mean absolute dystrophin level increased by 0.26% from baseline
▪️The 5 mg/kg dose was well-tolerated with no discontinu...

Trytosaveabit

Jul 30 16:04

Hmmm? Looks good to me?

$PepGen (PEPG.US)$ Hey Dr @Jaguar8 i need you! Hehehe. What exactly am i missing here??? I dont see it?? ((((. PepGen Shares Data From Low-Dose Cohort Of PGN-EDO51 In Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial For Treatment Of Duchenne Muscular Dystrophy; Says Was Well Tolerated, And All Patients Continued To Long-Term Extension Portion Of Trial. Dosing Of Second Cohort At 10 Mg/kg Is Ongoing
– PGN-EDO51 at 5 mg/kg was well tolerated, and all patients continued to long...

Meltyy

May 16 01:19

🔔 RA Capital Q1 ‘24* Holdings Released... 🐳

» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...

Trytosaveabit

Mar 13 06:05

$PepGen (PEPG.US)$ PepGen Receives U.S. FDA Orphan Drug And Rare Pediatric Disease Designations For PGN-EDO51 For The Treatment Of Duchenne Muscular Dystrophy

Moomoo AI

Jan 17 06:09

Mary Beth DeLena's addition to PepGen's executive team is viewed positively, her vast legal and compliance experience is anticipated to significantly contribute to PepGen's aim of providing next-gen oligonucleotide therapies for severe neuromuscular and neurological diseases.

Press Release: Mary Beth DeLena Joins PepGen as General Counsel and Secretary

I have just

Jan 10 15:59

PepGen Inc. dosed their first patient for the treatment of Duchenne muscular dystrophy (DMD)

$PepGen (PEPG.US)$
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the first patient has been dosed in its CONNECT1-EDO51 Phase 2, open-label multiple ascending dose (MAD) clinical trial evaluating PGN-EDO51 for the ...

Trytosaveabit

Jan 8 06:26

Will be watching for data to come

$PepGen (PEPG.US)$ PepGen Announced First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping
Benzinga· 5 mins ago

Trytosaveabit

Nov 9, 2023 05:53

Update! Watching!

$PepGen (PEPG.US)$ promising data from their 5mg/Kg dose level cohort, which is expected to be shared in mid-2024. This data suggests a high dystrophin expression, which is a strong indicator of PGN-EDO51’s effectiveness. In a head-to-head comparison with SRP-5051, PGN-EDO51 showed a 13-fold increase in exon skipping. Additionally, PepGen’s PGN-EDODM1 has shown promising early results, with significant correction of mis-splicing and myotonia after a single dose, and a tolerabili...

Trytosaveabit

Oct 12, 2023 06:35

Update

$PepGen (PEPG.US)$ The FDA Has Lifted The Full Clinical Hold And Cleared PepGen's Investigational New Drug Application To Initiate The FREEDOM-DM1 Phase 1 Study Of PGN-EDODM1 For Myotonic Dystrophy Type 1

Alvinnnnnnngenius

Sep 29, 2022 00:44

I actually missed this also

$PepGen (PEPG.US)$

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data